|
1
|
Gandhi JK, Tollefson TT and Telander DG:
Falciform macular folds and chromosome 22q11.2: Evidence in support
of a locus for familial exudative vitreoretinopathy (FEVR).
Ophthalmic Genet. 35:112–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pennock S, Haddock LJ, Mukai S and
Kazlauskas A: Vascular endothelial growth factor acts primarily via
platelet-derived growth factor receptor α to promote proliferative
vitreoretinopathy. Am J Pathol. 184:3052–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Radke NV, Panakanti TK, Radke SN and
Ravikoti R: Comment on ‘Intrasilicone oil injection of bevacizumab
at the end of retinal reattachment surgery for severe proliferative
vitreoretinopathy’. Eye (Lond). 28:15252014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robitaille JM, Gillett RM, LeBlanc MA,
Gaston D, Nightingale M, Mackley MP, Parkash S, Hathaway J, Thomas
A, Ells A, et al: Phenotypic overlap between familial exudative
vitreoretinopathy and microcephaly, lymphedema, and chorioretinal
dysplasia caused by KIF11 mutations. JAMA Ophthalmol.
132:1393–1399. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi H, Guo T, Liu PC, Wang QY, Du YR, Liu
QY, He MM, Liu JL and Yu J: Steroids as an adjunct for reducing the
incidence of proliferative vitreoretinopathy after rhegmatogenous
retinal detachment surgery: A systematic review and meta-analysis.
Drug Des Devel Ther. 9:1393–1400. 2015.PubMed/NCBI
|
|
6
|
Chiquet C and Rouberol F: Proliferative
vitreoretinopathy: Curative treatment. J Fr Ophtalmol. 37:653–659.
2014.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quiram PA, Drenser KA, Lai MM, Capone A Jr
and Trese MT: Treatment of vascularly active familial exudative
vitreoretinopathy with pegaptanib sodium (Macugen). Retina. 28 3
Suppl:S8–S12. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hussar DA: New drugs: Entecavir,
ibandronate sodium, and pegaptanib sodium. J Am Pharm Assoc (2003).
45:412–415. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moshfeghi AA and Puliafito CA: Pegaptanib
sodium for the treatment of neovascular age-related macular
degeneration. Expert Opin Investig Drugs. 14:671–682. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gonzales CR: VEGF Inhibition Study in
Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group:
Enhanced efficacy associated with early treatment of neovascular
age-related macular degeneration with pegaptanib sodium: An
exploratory analysis. Retina. 25:815–827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shukla D, Namperumalsamy P, Goldbaum M and
Cunningham ET Jr: Pegaptanib sodium for ocular vascular disease.
Indian J Ophthalmol. 55:427–430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rouberol F and Chiquet C: Proliferative
vitreoretinopathy: Pathophysiology and clinical diagnosis. J Fr
Ophtalmol. 37:557–565. 2014.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lane SS and Holland EJ: Loteprednol
etabonate 0.5% versus prednisolone acetate 1.0% for the treatment
of inflammation after cataract surgery. J Cataract Refract Surg.
39:168–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolfe JD and Hubbard GB III: Spontaneous
regression of subretinal exudate in coats disease. Arch Ophthalmol.
124:1208–1209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodriguez A, Rodriguez FJ, Valencia M and
Castaño C: Late development of a lamellar macular hole after the
spontaneous separation of vitreoretinal traction: Case report. Eur
J Ophthalmol. 26:e168–e170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodriguez A, Valencia M and Gomez FE:
Vitreoretinal traction and lamellar macular holes associated with
cicatricial toxoplasmic retinochoroiditis: Case series report. Eur
J Ophthalmol. 26:e128–e133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feist RM Jr, King JL, Morris R,
Witherspoon CD and Guidry C: Myofibroblast and extracellular matrix
origins in proliferative vitreoretinopathy. Graefes Arch Clin Exp
Ophthalmol. 252:347–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tosi GM, Marigliani D, Romeo N and Toti P:
Disease pathways in proliferative vitreoretinopathy: An ongoing
challenge. J Cell Physiol. 229:1577–1583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lipski A, Bornfeld N and Jurklies B:
Multifocal electroretinography in patients with exudative amd and
intravitreal treatment with pegaptanib sodium. Retina. 27:864–872.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ulinska M: Pegaptanib sodium in treatment
of wet AMD. Klin Oczna. 108:482–488. 2006.(In Polish). PubMed/NCBI
|
|
21
|
Foy JW, Rittenhouse K, Modi M and Patel M:
Local tolerance and systemic safety of pegaptanib sodium in the dog
and rabbit. J Ocul Pharmacol Ther. 23:452–466. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rinaldi M, Chiosi F, Dell'Omo R, Romano
MR, Parmeggiani F, Semeraro F, Menzione M and Costagliola C:
Intravitreal pegaptanib sodium (Macugen) for treatment of myopic
choroidal neovascularization: A morphologic and functional study.
Retina. 33:397–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishibashi T: LEVEL-J Study Group:
Maintenance therapy with pegaptanib sodium for neovascular
age-related macular degeneration: An exploratory study in Japanese
patients (LEVEL-J study). Jpn J Ophthalmol. 57:417–423. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ng EW and Adamis AP: Anti-VEGF aptamer
(pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad
Sci. 1082:151–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moysidis SN, Thanos A and Vavvas DG:
Mechanisms of inflammation in proliferative vitreoretinopathy: From
bench to bedside. Mediators Inflamm. 2012:8159372012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dombi T, Kwok KK and Sultan MB: A
retrospective, pooled data analysis of the safety of pegaptanib
sodium in the treatment of age-related macular degeneration in
subjects with or without diabetes mellitus. BMC Ophthalmol.
12:372012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tikhonovich MV, Iojleva EJ and Gavrilova
SA: The role of inflammation in the development of proliferative
vitreoretinopathy. Klin Med (Mosk). 93:14–20. 2015.(In Russian).
PubMed/NCBI
|
|
28
|
Rojas J, Fernandez I, Pastor JC, Maclaren
RE, Ramkissoon Y, Harsum S, Charteris DG, Van Meurs JC, Amarakoon
S, Ruiz-Moreno JM, et al: A genetic case-control study confirms the
implication of SMAD7 and TNF locus in the development of
proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci.
54:1665–1678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Keane-Myers AM, Miyazaki D, Liu G, Dekaris
I, Ono S and Dana MR: Prevention of allergic eye disease by
treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci.
40:3041–3046. 1999.PubMed/NCBI
|
|
30
|
Hocaoglu M, Karacorlu M, Sayman Muslubas
I, Ersoz MG and Arf S: Anatomical and functional outcomes following
vitrectomy for advanced familial exudative vitreoretinopathy: A
single surgeon's experience. Br J Ophthalmol. 101:946–950. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tikhonovich M, Lyskin P, Ioyleva E and
Gavrilova S: Expression of cyclooxygenases and trophic and growth
factors in epiretinal membranes at late stages of proliferative
vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 254:2277–2279.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sadaka A, Sisk RA, Osher JM, Toygar O,
Duncan MK and Riemann CD: Intravitreal methotrexate infusion for
proliferative vitreoretinopathy. Clin Ophthalmol. 10:1811–1817.
2016. View Article : Google Scholar : PubMed/NCBI
|
